Janux Therapeutics, Inc. (NASDAQ: JANX) is highlighted as one of the best small-cap biotech stocks to buy by analysts. Jones Trading remains bullish on JANX due to promising developments in the company’s prostate cancer program, with potential total addressable market in the U.S. estimated at $10 billion.

On November 11, 2025, Jones Trading’s Soumit Roy reiterated a “Buy” rating on Janux Therapeutics, Inc. (NASDAQ: JANX) citing mature data from Phase 1 trials and progress in T cell-engaging therapies for prostate cancer. JANX007 and JANX008 have shown significant advancements in the metastatic castration-resistant prostate cancer space.

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 results on November 7, 2025, with a net loss of $24.3 million, an improvement from the previous year. Strong momentum was seen in Phase 1 trials of lead candidates, with enhanced efficacy and durability of responses. The company also demonstrated disciplined cost management.

Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biopharmaceutical company specializing in developing novel immunotherapies using proprietary TRACTr and ARM platforms. While JANX shows investment potential, other AI stocks may offer greater upside and less downside risk according to analysts.

Read more at Yahoo Finance: Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program